alexa Research Advances in Pick’s Disease: A New Biomarker Candidate | OMICS International
ISSN: 2155-9562
Journal of Neurology & Neurophysiology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Research Advances in Pick’s Disease: A New Biomarker Candidate

Wenhui Hu1, and Jin Jun Luo2*

1Department of Neuroscience, Temple University School of Medicine, Philadelphia, USA

2Departments of Neurology and Pharmacology, Temple University School of Medicine, Philadelphia, USA

Corresponding Author:
Jin Jun Luo
Temple University School of Medicine
3401 North Broad Street
Philadelphia, USA
E-mail: [email protected]

Received date: December 11, 2012; Accepted date: December 18, 2012; Published date: December 20, 2012

Citation: Hu W, Luo JJ (2013) Research Advances in Pick’s Disease: A New Biomarker Candidate. J Neurol Neurophysiol 4:e112. doi:10.4172/2155-9562.1000e112

Copyright: © 2013 Hu W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Neurology & Neurophysiology

The eponym Pick’s disease (PiD) was named after Arnold Pick, a German neurologist, who first described this rare neurodegenerative disease in 1892 [1]. Current knowledge indicates that PiD is a member of a group of heterogeneous neurodegenerative disorders with similar or related histopathologic and clinical features known as frontotemporal lobal degeneration or dementia (FTD) [2,3]. FTD may also be called Pick complex [3] including PiD, primary progressive aphasia, semantic dementia, FTD with parkinsonism (FTDP) linked with chromosome-17, FTD with amyotrophic lateral sclerosis (FTDALS) linked to a newly identified gene named as C9ORF72 in the chromosome 9 open reading frame 72 [4], corticobasal degeneration (CBD) [5], and others [2,3]. FTD is the first or second most common cause of dementia among individuals younger than 60 years and the fourth most common cause of dementia in the USA. It has been noted that the incidence rates of FTD in 100,000 were 2.2 for ages 40 to 49, 3.3 for ages 50 to 59, and 8.9 for ages 60 to 69 [6], and range between 4% and 20% within dementia and 12% before the age of 65 [7]. Autopsy findings showed the occurrence between 2% and 20% [7-9]. Prevalence was estimated as 15 per 100,000 (8.4 to 27.0) in the 45- to 64-year-old population [10,11]. PiD affects individuals between the ages of 40 and 60 years old but can be seen individuals between 20 to 80 years old. A striking male preponderance (14:3) has been noted [11].

Pathologically, PiD is defined on the basis of histological appearance of neuronal loss and gliosis in severely circumscribed atrophy involving the anterior temporal and frontal lobes, the orbital frontal and the medial temporal lobes but sparing the posterior part of the superior temporal, the pre- and postcentral gyri, and parietal and occipital lobes [12]. The atrophy is usually worse on the dominant hemisphere. The ventricles, especially the frontal and temporal horns of the lateral ventricles, are enlarged. Pick cells and Pick bodies (PB), first described by Alois Alzheimer in 1911, are pathognomonic markers for PiD [13]. Pick cells are large, swollen, ballooned, diffusely argyrophilic neurons with vacuolated cytoplasm. They are common in the zones between severely affected and relatively preserved regions of the cortex and are also present in the cingulated gyrus, insular cortex, claustrum and occasionally in the anterior portion of the neostriatum. PB are argyrophilic intracellular spherical inclusions containing abnormal tau fibrils [14,15] arranged in a disorderly array. The major structural component of phosphorylated neurofilaments in PB is the microtubule-associated protein tau. In physiologic conditions, tau proteins are phosphorylated and assembled into filaments [16] exerting a fundamental role in axonal transport [17]. Abnormally phosphorylated and aggregated tau proteins are biochemical markers of various forms of neurodegenerative dementias, including AD, PiD, CBD, PSP, and FTDP, collectively called tauopathies [14,18]. PB are mostly located in the layers II, III and IV of the neocortex [19,20] . PB can be detected with various antibodies including those to tau, ubiquitin, alpha-synuclein, apolipoprotein E, N-terminal amyloid precursor protein, Alz-50, clathrin, synaptophysin, neuronal surface glycoside, and βII tubulin. Antibodies to abnormally phosphorylated tau proteinsare the best markers for PB and Pick cells [21]. Additionally, silver stains can be useful in distinguishing PiD from AD [22].

The etiological role of tau proteins in neurodegeneration has been studied through the identification of mutations in Tau in the familial form of dementia and/or parkinsonism [23,24]. The gene that encodes tau is on chromosome 17q21. In an adult human brain there are six tau isoforms. Alternative splicing of exons 2, 3, and 10 within the tau gene produces 6 isoforms that create 3 or 4 repeats of the microtubule binding domain of tau. Altering this ratio of 4-repeats to 3-repeats results in various pathologies. For example, AD exhibits 6 tau isoforms, 4-repeat tau is more common in CBD and PSP, whereas initial studies showed PiD has only 3-repeat isoforms [25] however, subsequent studies showed there is equal frequency of 4-repeat to 3-repeat tau in PiD [26].

Based on the immunocytochemical findings, FTD may be further classified into three subtypes [12,27]. Type A is the classic PiD, characterized by front temporal and limbic degeneration with PB and Pick cells. Type B has superior frontal and parietal atrophy with Pick cells but no PB which can be seen in CBD or FTDP with asymmetrical corticospinal and extra pyramidal symptoms and signs, and degeneration of the cortex, substantia nigra, striatum, and other deep nuclei. Type C is characterized by the absence of both PB and Pick cells with either circumscribed or diffuse cortical atrophy with varying involvement of deep nuclei [12,19].

Clinically, there are two core PiD symptomatic patterns involving behavior and language. Features of behavioral changes can be either impulsive (disinhibited) or bored (apathetic) and include inappropriate social behavior; lack of social tact or empathy; loss of insight into the behaviors of oneself and others; an increased interest in sex; changes in food preferences; agitation or, conversely, blunted emotions; neglect of personal hygiene; repetitive or compulsive behavior, and decreased energy and motivation. Features of language disturbance include difficulty in making or understanding speech, often in conjunction with abnormal behavioral symptoms but with intact spatial skills and memory [3,14,15].

On neurologic examination, PiD patients typically show frontal release signs of primitive, such as grasp and palmomental, reflexes. Extrapyramidal features such as rigidity, gait instability, a masked face, and micrographia are frequently encountered but a resting tremor is rare. Fasciculation, muscle wasting, motor weakness, swallowing difficulty with an attenuated gag reflex and effortful speech may be seen [3,14,15]. Signs of ocular and cerebellar dysfunctions such as ataxia, dysmetria, and sensory defects are not typically associated with PiD. Because of no specific neurologic signs for the diagnosis of PiD, cognitive and behavioral tests are usually applied. Detailed neuropsychologic test batteries have been developed to help, but many of these comparative studies have limitations, in distinguishing dementia between PiD and AD [28]. The Mini Mental State Examination (MMSE) is not a sensitive tool for screening patients with PiD, since profoundly impaired PiD patients can have a normal MMSE [29]. Atrophy of front and temporal lobes is demonstrated by neuroimaging such as brain CT or MRI. The lobar hypoperfusion is displayed by functional neuroimaging such as single-photon emission computed tomography. However, the gold standard for the diagnosis of FTD is neuropathology.

There is no specific treatment for PiD. No clinical trials have been conducted. Empirically treating PiD patients with cholinesterase inhibitors, antidepressants, selective serotonin reuptake inhibitors, and antipsychotics showed no satisfactory effects. PiD progresses steadily and often rapidly, ranging from less than 2 years to more than 10 years, with an average approximately 6 years [30]. Notably, PiD patients with main symptoms of speech and language disturbance (primary progressive aphasia) may survive 5 years longer than those with behavioral symptoms (behavioral variant) [31], and may preserve the ability to function at home for 10 or more years after onset.

The cause of PiD is unknown. Familial forms of Pick-complex dementias has been found to be linked to chromosome 17, 9, and 3 [3]. The familial form is approximately 30-40% of all FTD cases but tau mutation has been found only in approximate 10% of the families tested, and not in any sporadic cases [10]. In addition to the tau mutation, TDP-43 gene mutation is identified in FTDP and FTD-ALS [2,32]. TDP-43 is a major component of inclusions in ALS. In transgenic mice TDP-43 causes spinal and frontal neurodegeneration without protein aggregations, indicating that the mechanisms for the development of the disease is likely due to altered function of the DNA/RNA binding rather than a toxic effect of the protein [33].

In a recently published issue in the Journal of Neurology and neurophysiology, Nishijima et al. [34] reported a possible biomarker candidate named calmodulin-like skin protein (CLSP) for PiD. They identified CLSP from a solubilized PB sample using a laser-microdissection system and Unfoldin-modified proteomic analysis. Unfoldin, named by the authors, was purified from yeast cells consisting of a homo-oligomer of 10–12 subunits, each of which is identical to Aip2p/Dld2p from YDL178w yeast. These authors found that Unfoldin can effectively solubilize aggregated proteins including PB in PiD [35]. Therefore, Unfoldin-solubilized samples can be used for many downstream analyses such as immunoblotting, immunoprecipitation, protein sequencing, etc. While their study advances our understanding of PB in PiD, caution is warranted in interpreting the results. As a novel biomarker candidate for PiD, CLSP needs further confirmation. Studies using immunofluorescent double staining and confocal imaging analysis in tissue sections may be helpful to demonstrate the colocalization of CLSP and abnormally phosphorylated tau protein in PiD. Because extracellular PB may lose tau immunoreactivity due to proteolysis [36], the possibility of changes in PB antigenicity after Unfoldin-treatment should be tested. It would be interesting to know whether CLSP is expressed specifically or nonspecifically in PB, for example, chromogranin A staining of PB can be observed in other neurodegenerative disorders [37].

Dementia is a natural dilemma in a human’s life. Advanced technology with scrutinized clinical and laboratory research would help shed more light on the pathogenesis of PiD and to establish a strategy applicable to early diagnosis, effective treatment and, possibly, prevention of PiD in the future.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 12486
  • [From(publication date):
    February-2013 - Mar 25, 2018]
  • Breakdown by view type
  • HTML page views : 8704
  • PDF downloads : 3782

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version